

# 2022 PORTON CSR REPORT

TO BE THE MOST OPEN, INNOVATIVE AND RELIABLE PHARMACEUTICAL  
SERVICE PLATFORM IN THE WORLD

ENABLING THE PUBLIC'S EARLY ACCESS TO GOOD MEDICINES



Porton on WeChat



Porton on  
WeChat Video  
Channel

**Porton Pharma Solutions Ltd.**

Address: Fangzheng Avenue, Shuitu, Beibei District, Chongqing, China

Tel: 86-23-65936900

Email: [porton.db@porton.cn](mailto:porton.db@porton.cn)





# CONTENTS

<b>ABOUT THIS REPORT</b> .....	<b>03</b>	<b>EMPOWER EMPLOYEE DEVELOPMENT</b> .....	<b>25</b>
<b>TERMINOLOGY AND DEFINITIONS</b> .....	<b>04</b>	Employment	27
<b>CHAIRMAN'S MESSAGE</b> .....	<b>05</b>	Remuneration and Benefits	28
<b>STAKEHOLDER MANAGEMENT</b> .....	<b>06</b>	Talent Development	28
<b>HONORS AND MEMBERSHIPS</b> .....	<b>07</b>	Employees Communication	29
<b>ABOUT PORTON</b> .....	<b>09</b>	Cultural Co-construction	30
		Occupational Health and Safety	30
<b>IMPROVE CORPORATE GOVERNANCE</b> .....	<b>11</b>	<b>PRACTICE GREEN DEVELOPMENT</b> .....	<b>31</b>
Corporate Governance	13	EHS Management	33
Risk Management and Honest Operations	15	Green Chemistry	33
Information Security	17	Pollution Governance	35
Protection of Intellectual Property	18	Risk Prevention and Control	36
		Green, Low-carbon, Energy Conservation and Emission Reduction Practices	36
<b>PROVIDE HIGH-QUALITY SERVICES</b> .....	<b>19</b>	<b>PARTICIPATE IN COMMUNITY CO-DEVELOPMENT</b> .....	<b>37</b>
Customer Services	21	Industry Cooperation	39
Quality Management	22	Public Welfare Activities	39
Technology Innovation	23		
Production and Operation	24	<b>KEY PERFORMANCE INDICATORS</b> .....	<b>43</b>
Sustainable Supply Chain	24	<b>APPENDICES</b> .....	<b>45</b>
		GRI Indicator Index	45
		Feedback Form	47

# ABOUT THIS REPORT

The 2022 CSR Report is the 7th CSR report released by Porton Pharma Solutions Ltd. and aims to state the Company’s efforts and achievements as a socially responsible corporate citizen.

## REPORTING PERIOD

This Report covers the period from 1 January 2022 to 31 December 2022. For the sake of consistency and comparability of information, this Report includes necessary historical data.

## SCOPE OF THIS REPORT

This Report is primarily about Porton Pharma Solutions Ltd. and its subsidiaries. For the convenience of expression, in this Report, “Porton Pharma Solutions Ltd.” is referred to as “Porton”, “the Company” or “we”; “Porton Pharma (Jiangxi) Co., Ltd.” as “Porton Jiangxi”; “Porton Advanced Solutions Ltd.” as “Porton Advanced”; “Porton Pharmatech Co., Ltd.” as “Porton Pharmatech”; “Hubei Yuyang Pharmaceutical Co., Ltd.” as “Hubei Yuyang”; and “China Gateway Pharmaceutical Development Co., Ltd.” as “Gateway Pharmaceutical”.

## REPORTING CYCLE

The report is released annually.

## DATA SOURCE OF THIS REPORT

The data used in this Report are derived from the Company’s public documents, internal documents, and relevant statistics. Unless otherwise specified, the monetary unit in this Report shall be RMB.

## REPORTING STANDARDS

This Report has been prepared by referring to the Global Reporting Initiative *Sustainability Reporting Guidelines (the “GRI Standards”)*, the *Guidance on Social Responsibility (ISO26000)* issued by the International Organization for Standardization, and the *Guidelines on Corporate Social Responsibility Reporting for Chinese Enterprises (CASS-CSR3.0)*.

## REPORT ASSURANCE

The Board of Directors of the Company (the “Board”) as a whole and each member of the Board undertake that the contents of this Report are free of any misrepresentations, misleading statements or material omissions, and shall collectively and individually accept legal responsibility for the truthfulness, accuracy and completeness of such contents.

## REPORT ACCESS AND CONTACT INFORMATION

This Report is published in electronic form, which is available for download at

[www.portonpharma.com](http://www.portonpharma.com)

Address: Fangzheng Avenue, Shuitu, Beibei District, Chongqing, China

Tel: +86 23-65936900

E-mail: [porton.db@porton.cn](mailto:porton.db@porton.cn)

# TERMINOLOGY AND DEFINITIONS

ITEM	DEFINITION
<b>CRO</b>	Contract Research Organization
<b>CMO</b>	Contract Manufacturing Organization
<b>CDMO</b>	Contract Development and Manufacturing Organization
<b>API</b>	Active Pharmaceutical Ingredient
<b>WHO</b>	World Health Organization
<b>FDA</b>	Food and Drug Administration
<b>PMDA</b>	Pharmaceuticals and Medical Devices Agency
<b>NMPA</b>	National Medical Products Administration
<b>EMA</b>	European Medicines Agency
<b>GMP</b>	Good Manufacturing Practice
<b>EDR</b>	Endpoint Detection & Response
<b>PCT</b>	Patent Cooperation Treaty
<b>SFC</b>	Supercritical Fluid Chromatography, refers to a chromatographic separation method with supercritical fluid as the mobile phase
<b>PCC</b>	Preclinical Candidate Compounds
<b>EHS</b>	Environment, Health and Safety
<b>DoE</b>	Design of Experiment

# CHAIRMAN'S MESSAGE

Dear Stakeholders,

2022 was a remarkable year for Porton, despite of all the macro environment challenges such as the geopolitical conflict, the Covid-19 pandemic and summer heat. We obtained the biggest order ever in the Company's history and made a near-perfect delivery for the best results the Company has ever recorded. Moreover, we continued to invest in global and end-to-end service capabilities, new competence, new production capacity, and digitalization. In face of uncertainties, we were able to maintain a strong strategic position while looking for opportunities for breakthroughs and innovation. In the meantime, we have become more aware that in order to achieve more resilient and higher quality sustainable development, we must adhere to long-termism and a development model that balances economic benefits with governance, environmental and social benefits to continuously improve our resilience to risks and sustainability.



**Nianfeng JU**  
Chairman and CEO

We are committed to sustainable development and integrate ESG (environment, social and governance) concepts into our daily operations. We continue to pay attention to the needs of our customers, employees, shareholders, suppliers, partners, communities and other stakeholders and respond actively to them. We continue to improve our governance and compliance systems and operate in compliance. We uphold our core value of "Customers First" and are committed to providing reliable products and services to our customers. We promote diversity and strive to provide a safe, equal and inclusive workplace for our employees. We adhere to green development and continue to strengthen our EHS system. We continue to build a sustainable supply chain and enhance the management of our suppliers. What's more, we take our social responsibility seriously and actively participate in social welfare activities.

Looking towards 2023, although the internal and external challenges are ongoing, we will begin our new three-year strategic cycle, when six major strategies will be adopted. They are achieving breakthroughs in key business opportunities, developing new business, making breakthroughs in key technologies, marketing reform, digital transformation, and globalization. By achieving breakthroughs in key markets, key customers, and key products, we will continue to invest and transform our core business and organizational capabilities to enhance customer value and business competitiveness, as well as to maintain our long-term competitiveness. At the same time, we will also gradually improve the ESG governance system and promote the continuous improvement of ESG management capabilities through initiatives such as improving the policy system, formulating ESG objectives, refining work plans and improving ESG disclosure.

Embedded in our DNA is a corporate social responsibility to help clients develop life-saving medicines by providing reliable services and delivery. Moving forward, we will continue to adopt ESG practices and work together with our global partners to achieve sustainable development.

# STAKEHOLDER MANAGEMENT

STAKEHOLDERS	DEMANDS	THE COMPANY'S RESPONSE
 <b>SHAREHOLDERS AND INVESTORS</b>	<ul style="list-style-type: none"> <li>• Protection of shareholders' rights and interests</li> <li>• Good operating conditions</li> <li>• Continued earnings</li> <li>• Fairness, just and openness</li> </ul>	<ul style="list-style-type: none"> <li>• Improve corporate governance mechanism</li> <li>• Strengthen the construction of internal control management system</li> <li>• Enhance risk prevention and control</li> <li>• Disclose operating information and financial reports in a transparent and open manner</li> <li>• Keep communicating with shareholders and investors</li> </ul>
 <b>GOVERNMENT</b>	<ul style="list-style-type: none"> <li>• Legal and compliant operations</li> <li>• Honest tax payment</li> <li>• Create a good business environment</li> <li>• Guarantee safe production and stable operations</li> <li>• Actively drive employment</li> <li>• Cooperate with policies</li> </ul>	<ul style="list-style-type: none"> <li>• Comply with laws and regulations</li> <li>• Tax payment according to laws</li> <li>• Communicate and cooperate with the government in social governance</li> <li>• Continuously strengthen production safety management</li> <li>• Actively create job opportunities to develop local talents</li> </ul>
 <b>CUSTOMERS</b>	<ul style="list-style-type: none"> <li>• Integrity operation</li> <li>• Provide safe and reliable products</li> <li>• Provide high-quality services</li> <li>• Protect clients' trade secrets</li> </ul>	<ul style="list-style-type: none"> <li>• Serve clients with honesty and trustworthiness</li> <li>• Provide products and services that meet clients' demands and expectations</li> <li>• Treat clients with good faith and strive to improve customer satisfaction</li> <li>• Protect clients' business secrets from being leaked</li> <li>• Improve relevant client management system</li> </ul>
 <b>PARTNERS</b>	<ul style="list-style-type: none"> <li>• Abide by business ethics</li> <li>• Fair competition</li> <li>• Fair, just and open procurement</li> <li>• Mutual help and benefit for co-development</li> </ul>	<ul style="list-style-type: none"> <li>• Honest business cooperation</li> <li>• Advocate healthy industrial competition</li> <li>• Conduct responsible sourcing</li> <li>• Improve relevant supplier management system</li> </ul>
 <b>EMPLOYEES</b>	<ul style="list-style-type: none"> <li>• Protect legitimate rights and interests</li> <li>• Provide occupational health and safety guarantee</li> <li>• Provide career development and promotion channels</li> <li>• Comfortable work environment</li> <li>• Effective communication channels</li> </ul>	<ul style="list-style-type: none"> <li>• Pay salaries, social security and housing provident fund according to the law in full and on time</li> <li>• Provide equal job opportunities</li> <li>• Provide professional and personalized career training and promotion channels</li> <li>• Provide occupational health and safety training</li> <li>• Advocate democratic management and broaden communication channels</li> <li>• Establish a platform for employees' voices to timely answer their relevant questions</li> </ul>
 <b>ENVIRONMENT</b>	<ul style="list-style-type: none"> <li>• Implement energy conservation and emission reduction policies and regulations</li> <li>• Regulations in China and abroad</li> <li>• Realize green management and green operations</li> <li>• Protect the ecological environment</li> </ul>	<ul style="list-style-type: none"> <li>• Establish corporate green management system</li> <li>• Carry out energy conservation and emission reduction in all aspects</li> <li>• Implement green design, green manufacturing, and green services</li> <li>• Implement green office</li> <li>• Practice green charity</li> </ul>
 <b>COMMUNITIES</b>	<ul style="list-style-type: none"> <li>• Promote community development</li> <li>• Support public welfare</li> <li>• Build special public welfare projects</li> </ul>	<ul style="list-style-type: none"> <li>• Carry out volunteer activities</li> <li>• Encourage employees to participate in public welfare</li> <li>• Participate in community construction</li> </ul>



# HONORS AND MEMBERSHIPS

## HONORS

AWARDS AND RECOGNITION	RECIPIENT	ORGANIZER
Key Enterprise Integrating Information Technology Outsourcing and Manufacturing	Porton	Ministry of Commerce of the People's Republic of China
2021 Top 20 Chinese CXO Enterprise	Porton	Top 100 Expert Committee in China's Pharmaceutical Industry
2022 Top 20 Most Influential CXO Enterprise	Porton	Organizing Committee of China Biomedical Innovation Cooperation Conference
2022 Top 20 Most Influential and Innovative CXO Enterprise	Porton	Organizing Committee of China's Biotechnological and Medical Innovation Forum
2022 Top 20 Chinese Pharmaceutical CDMO Enterprise	Porton	Organizing Committee of China's Medical Health Industrial Development Conference
2022 Top 100 Private Enterprise in Chongqing	Porton	Chongqing Federation of Industry and Commerce, Chongqing Municipal Science and Technology Bureau, and Chongqing Municipal Economic and Information Committee
2022 Top 100 Manufacturing Enterprise in Chongqing	Porton	Chongqing Federation of Industry and Commerce and Chongqing Municipal Economic and Information Committee
Chongqing Innovation Demonstration Smart Plant	Porton	Chongqing Municipal Economic and Information Committee
2022 Digital Innovation Model Award	Porton	Organizing Committee of the 2022 International Sci-tech Innovation Festival
2022 Top 10 Chinese Pharmaceutical Listed Company with Most ESG Investment Value	Porton	E Medical Manager
Excellent Practice Case for the 2021 Annual Report Results Presentation by Listed Companies	Porton	China Association for Listed Companies
Extraordinary Employer of 2022	Porton	Liepin
Environmentally-friendly and Honest Enterprise	Porton	Liangjiang New District Sub-bureau of Chongqing Municipal Bureau of Ecology and Environment

Excellent Enterprise Regarding Production Safety in Changshou District in 2021	Porton	Municipal People's Government of Changshou District, Chongqing
Digital Plant of Chongqing	Porton Pharmatech	Chongqing Municipal Economic and Information Committee
Advanced Enterprise Regarding Production Safety in 2021	Porton Jiangxi	Fengxin County People's Government of Jiangxi
Top 10 Excellent Enterprise in 2021	Porton Jiangxi	Working and Management Committees of Fengxin High-tech Industrial Park of the Communist Party of China
Top 10 Enterprise in Tax Contribution in 2021	Porton Jiangxi	Working and Management Committees of Fengxin High-tech Industrial Park of the Communist Party of China
Advanced Enterprise in Innovative Development in 2021	Porton Jiangxi	Working and Management Committees of Fengxin High-tech Industrial Park of the Communist Party of China
Advanced Enterprise in Green Development in 2021	Porton Jiangxi	Working and Management Committees of Fengxin High-tech Industrial Park of the Communist Party of China
Advanced Grassroots Party Organization in 2022	Porton Jiangxi	Working Committee of Jiangxi Fengxin High-tech Industrial Park of the Communist Party of China
Top 10 CXO with Growth Potential in 2022	Porton Advanced	Organizing Committee of China Biomedical Innovation Cooperation Conference
2022 Excellent CDMO Award	Porton Advanced	Organizing Committee of BioCon Awards 2022
Employer with the Greatest Growth Potential in 2022	Porton Advanced	Suzhou Best Employer Committee

## MEMBERSHIPS

ORGANIZATION/INSTITUTION	MEMBERSHIP	ENTITY
The United Nations Global Compact (UN Global Compact)	Member	Porton
Sino-American Pharmaceutical Professionals Association-China (SAPA)	Member of the Director Organization	Porton
American Chemical Society Green Chemistry Institute (ACS GCI) Pharmaceutical Roundtable	Associate Member	Porton
China Association of Chemical Safety	Member Organization	Porton
Board of Governors "Advances in Pharmacy"	Standing Director Organization	Porton
China Alliance for Rare Diseases	Member	Porton Advanced



# ABOUT PORTON

Founded in 2005, Porton (SZ.300363) is an internationally recognized pharmaceutical contract development and manufacturing organization (CDMO) in enabling our global clients to optimize drug development and manufacturing. We provide our customers development and manufacturing services for chemical drugs (including registered starting materials, intermediates, APIs, and drug products), biologics, and gene and cell therapies from pre-clinical to commercialization. The Company has R&D, manufacturing and operating facilities across China (including Chongqing, Chengdu, Shanghai, Yichun, Yingcheng, Suzhou, and Hong Kong), the United States, Belgium, Switzerland, Denmark and Slovenia with over 5,300 employees worldwide.

Our Process Technology Centers and WHO/USFDA/EMA/PDMA/NMPA-inspected Manufacturing Facilities feature state-of-the-art equipment, highly flexible cGMP-compliant production assets, plus around 1700 highly skilled scientists and process engineers, all backed by a proven program management system dedicated to seamlessly delivering successful outcomes for customers' unique project requirements.

We are committed to be the most open, innovative and reliable pharmaceutical service platform in the world and enabling the public's early access to good medicines. We constantly strive for excellence, and have been recognized through awards by industry forums and global pharmaceutical companies for our process innovation, supply chain performance and compliance with global Quality and EHS standards. By efficiently advancing development and enabling commercialization of multiple high-impact medicines, Porton is proud to have earned the trust of some of the world's leading and most innovative pharmaceutical companies and many biotechnology companies across the US, EU and Asia.

**7.04** billion  
Revenue

**~800**  
Global Clients

**5332**  
Number Of Employees

**2.01** billion  
Net Profit Attributable to Shareholders of the Listed Company

**2200+**  
Successful Projects

**20+**  
Operation Facilities

## VISION

To be the most open, innovative and reliable pharmaceutical service platform in the world

## CORE VALUES

### CUSTOMERS FIRST

- Exceeding customers' expectations is our highest pursuit.
- Understand customers' needs in a proactive way and actively provide optimal solutions.
- Strive for the best outcome and highest level of customer satisfaction in each project.
- All activities are aimed at enhancing customer satisfaction.

### PURSUIT OF EXCELLENCE

- Yesterday's best is today's starting point.
- Learn from the best in every field.
- Embrace criticism and self-criticism to foster a better team and a better self.
- Perform regular reviews of the past for continuous improvement.

### TEAMWORK

- Align well with team and company goals.
- Be sincere and professional, build mutual understanding, support, and trust.
- Cooperate actively and fully support each other.
- Communicate proactively, timely and openly.

## MISSION

Enabling the public's early access to good medicines


### EFFICIENT EXECUTION

- Pursue goals with commitment.
- Conduct open and fair discussions, and execute unconditionally once decisions are made.
- Dare to take responsibilities.
- When in challenging situation, seek support timely while trying your best.

### EMBRACE CHANGES

- Sustained success is the purpose of making changes.
- Keep learning and improving to adapt to the changing environment.
- Keep an open mind and actively initiate and drive changes.
- Have the courage to innovate and keep exploring new approaches.

## PORTON'S BUSINESS SEGMENTS





# IMPROVE CORPORATE GOVERNANCE


Corporate Governance  
Risk Management and  
Honest Operations  
Information Security  
Protection of  
Intellectual Property





## CORPORATE GOVERNANCE

The Company strictly follows the requirements of relevant laws, regulations and regulatory documents, keeps improving the governance structure, establishes and improves the decision-making mechanism and relevant systems, and continuously enhances the governance level to lay a solid foundation for its sustainable and stable development.




During the Reporting Period, the General Meeting of Shareholders, the Board of Directors and its special committees, and the Board of Supervisors all operated effectively and independently in accordance with the relevant laws and regulations, the Articles of Association, and the rules of procedure of the Company.

### GENERAL MEETING OF SHAREHOLDERS

The Company convenes general meetings of shareholders in accordance with relevant requirements, treats all shareholders equally, and protects the full exercise of rights by all shareholders, especially small and medium shareholders. During the Reporting Period, the Company held three general meetings of shareholders in total.

### BOARD OF DIRECTORS

The Company is committed to promoting the diversity of the Board of Directors. During the Reporting Period, the Company completed the re-election of directors and supervisors as the term of office of last session ended. The new Board of Directors consists of nine members, including one executive director, five non-executive directors and three independent directors, three of whom were female. The Company's directors have good educational background and industry experience, covering different professional fields like healthcare industry, finance, law, strategy, and investment, nearly half of whom hold doctoral degrees. During the Reporting Period, the Company convened a total of 15 board meetings in accordance with relevant laws and regulations, and all directors diligently fulfilled their duties, paid attention to the Company's operations management, financial conditions and other material matters, actively participated in decision-making of the Company's major issues, and made professional suggestions on the Company's governance norms and other aspects based on their professional knowledge and abilities.



3  
GENERAL MEETINGS OF SHAREHOLDERS

15  
MEETINGS OF BOARD OF DIRECTORS

11  
MEETINGS OF BOARD OF SUPERVISORS

4  
PERIODIC REPORTS

192  
TEMPORARY ANNOUNCEMENTS

### BOARD OF SUPERVISORS

The Board of Supervisors of the Company consists of three members, including one employee supervisor, and two members are female. During the Reporting Period, the Company held 11 meetings of the Supervisory meeting in accordance with relevant regulations, and the Board of Supervisors conscientiously performed its supervisory duties and effectively supervised the Company's operations management, internal control situation, financial condition, and other matters.

### INFORMATION DISCLOSURE

The Company discloses information in a true, accurate, complete, timely, and fair manner in strict accordance with relevant laws and regulations, strives for concise, clear, and easy-to-understand disclosure, and continues to optimize the content and forms of periodic reports to enhance their readability. In addition to matters that are legally required to be disclosed, the Company also makes voluntary disclosures on matters that do not meet the legal disclosure standards but have a significant impact on the Company's operations to ensure that investors have a timely, accurate, and comprehensive understanding of the Company's operations through information disclosure. During the Reporting Period, the Company disclosed a total of 196 announcements through the media that meet the requirements of the China Securities Regulatory Commission (CSRC): *China Securities Journal*, *Shanghai Securities News*, *Securities Times*, *Securities Daily*, and the cninfo website ([www.cninfo.com.cn](http://www.cninfo.com.cn)).

### INVESTOR RELATIONS MANAGEMENT

Attaching importance to the protection of shareholders' and investors' equity interests, the Company has formed a top-down investor relations mechanism and has launched investor relations activities through diversified channels. In 2022, the Company organized and participated in many investor communication activities, including performance briefing, investment conferences, on-site meetings, etc., to maintain high-frequency communication with the capital market, actively focus on and explore investors' needs, and give timely responses. In March 2022, the Company held the annual performance briefing for 2021 in the form of live video broadcast with supporting of presentation material for the first time. The management team, including the chairman, general manager, board secretary, independent directors, and heads of various business segments, communicated with investors. The briefing was viewed online more than 76,000 times and received positive feedback from investors.



Annual Performance Briefing for 2021

During the Reporting Period, the Company was selected as an excellent practice case for listed companies' 2021 annual performance briefing by the China Association for Public Companies, and won the 2021 Panorama Investor Relations Gold Award and the Roadshow China IR Excellence Award for Best Capital Market Communication.

The Company continues to reward its shareholders and has paid cash dividends every year since its listing, with the cumulative amount of dividend payouts reaching RMB 1.1 billion.



## RISK MANAGEMENT AND HONEST OPERATIONS

**100%**  
TRAINING COVERAGE FOR BUSINESS ETHICS

**0%**  
LAWSUIT INVOLVING ANTI-CORRUPTION

The Company strictly abides by the laws and regulations of each operation place, follows the principles of integrity, law-abiding, honesty, and truthfulness, and carries out compliant and trustworthy operations. On the one hand, the Company has established internal control policies such as *the Internal Control Management System* and the *Management System for Majority-owned Subsidiaries* to promote the standardized operation of the Company and its subsidiaries. The Company has also set up the Risk Management Committee to identify and assess various risks associated with the Company's business activities and implement risk management plans to strengthen the Company's risk management. On the other hand, the Company roots its awareness of compliance in operational development and has established the *Code of Business Conduct*, the *Employee Handbook*, the *Whistleblowing and Complaint Management System*, the *Employee Reward and Punishment Management System*, and other systems to regulate behaviors involving corruption, bribery, unfair competition, insider trading, conflict of interest, leakage of confidentiality, discrimination, and other aspects, and to stipulate the punishment methods for violating the corresponding regulations. In addition, the Company's senior executives have signed the *Integrity Agreement* to ensure that the Company abides by business ethics from top to bottom. The Company also continues to increase the publicity of compliance concepts through new employee induction compliance training, daily compliance training, internal compliance publicity, etc. to continuously prompt employees' compliance awareness in all aspects and establish a compliance culture.

Either the contracts the Company signed with clients, suppliers, and other partners will include clauses or we will sign a separate integrity agreement. For example, the integrity clause of the procurement contract clearly stipulates that in the procurement process, if there is evidence that the supplier has offered bribes to the procurement staff of the demand side to achieve its business purposes, the demand side will cancel its supply qualification and refuse to pay for the goods. The Company's reporting channels are also published in integrity clauses. Suppliers can also report to the Company any fraud they find, and the Company actively encourages and rewards suppliers for reporting bribes demanded from suppliers by procurement staff on the demand side.

The Company conducts quarterly compliance audits, special audits, process audits, special inspections, special anti-fraud investigations, etc. to identify compliance issues in a timely manner and promote punishment and rectification. In September 2022, the Audit Department, which is responsible for internal audit, was renamed as the Audit and Supervision Department, with additional supervisory duties and authority based on the original internal audit duties, to carry out internal supervision independently in accordance with laws, regulations, and the Company's supervisory management system. The Department independently exercise the supervisory right, within the scope of authorization, to monitor and investigate the suspected major violations of law, irregularities, misappropriation of duties, abuse of power, transfer of benefits, favoritism and fraud, as well as damage to and waste of the Company's assets in the Company and its subsidiaries and to propose treatment suggestions in accordance with the relevant regulations of the Company. The Company's internal audit department also actively maintains communication with external auditors to link up with each other and collaborate to continuously promote the Company's internal control compliance construction.

The Company encourages supervision and reporting. *The Reporting and Complaint Management System* stipulates the definitions of reporting and complaints, responsible departments, channels, and rewards and also expressly requires that investigators should pay special attention to good confidentiality and strictly prohibit the disclosure of the name, unit, address, and other information of the whistleblower. Clauses were set up to protect the whistleblowers and complainants: The information reported or materials involving the personal information of the whistleblower shall not be shown or disclosed to the reported department or the investigated person and the personnel involved in the investigation of the reported case who has relative or interest relationship with the investigated person shall recuse himself or herself from the case. The Company will also take all necessary confidentiality measures to protect the rights and interests of employees who report or file complaints from being compromised.






## INFORMATION SECURITY

The Company attaches great importance to its information security protection and continues to improve the information security management system. It has stipulated the information security management policies, information security management procedures, security incident management, security risk management, information security education, code of conduct and penalties for violations through the formulated policy systems such as *Information Security Management Policy* and *Information Security Incident Management System*. During the Reporting Period, the Company passed the Authentication of Information Security Management System (ISO27001), signifying that the Company's information security management system has been recognized by international standards.



Obtained ISO27001 Information Security Management System Certification



### PHYSICAL SECURITY MANAGEMENT

The Company implements full management to ensure the security and traceability of information, including the Company's peripheral electronic fence, monitoring of key areas, access control management of confidential areas, printing and copying management, computer management, etc.

### INFORMATION ASSET AND NETWORK SECURITY MANAGEMENT

- Conduct confidential management of data assets and permission management of software/systems;
- Formulate the *Information Management System* and release the online approval process to regulate the management of the Company's external information security in terms of information disclosure, official document submission, and press release;
- Make detailed regulations for computer information security management in the project process and further ensure information security by measures like drawing security red lines and rising approval levels on the basis of the existing *Information Security Management Policy* and *Mailbox Security Management System*;
- Upgrade the *Mail System Security Management System* and enable the mobile mailbox data leakage prevention strategy to systematically and technically improve the Company's data protection capability at the mobile end;
- Promote the installation of EDR software on office computers throughout the Company and deploy a mobile control platform to manage company-issued mobile terminal devices and strengthen active protection and control against network threats and data leakage of terminals;
- Add the *Feishu Collaborative Office System Management System* to control the external sharing and communication permissions of Feishu through process review and approval;
- Staff in some key positions use the Company's virtual cloud desktop to achieve data off the ground and protect information security;
- Control information sharing permissions and audit sharing records;
- Control network permissions and upgrade the Internet Access Management System to strengthen control.

## INFORMATION SYSTEM SECURITY MANAGEMENT

The Company follows the principle of minimal permissions for permission allocation and protection strategy configuration and the system should undergo vulnerability scanning, penetration testing, disaster recovery, backup, and other security assessments by the security team before going online. Only through system backups, recovery drills and security assessments can the system go live. The system will be regularly updated with security patches and undergo penetration tests, vulnerability scans, and backup data verification tests after entering the operation and maintenance phase to analyze the current security protection strategy, attack sources, and attack target systems and adjust the protection strategy in time based on the analysis results.

## INFORMATION SECURITY TRAINING

The Company's information security engineers conduct quarterly onboarding network information security training for new employees, so employees can correctly carry out prevention, response, and disposal before/in/after network threat to improve the Company's overall capability and awareness of network information security protection.

## PROTECTION OF INTELLECTUAL PROPERTY

The Company always attaches great importance to the management and protection of intellectual property, continues to strengthen the construction and efforts of intellectual property management system, and strictly protects the intellectual property rights of customers, partners, and itself, with zero tolerance for intellectual property infringement. In addition, the Company continuously strengthens the construction of intellectual property security culture. Employees are regularly trained in trade secret protection by year. New employees all need to participate in intellectual property and trade secret protection training and pass the intellectual property protection test when joining the Company. The Company also maintains a weekly publicity for intellectual property rights-related contents through its online platform to promote intellectual property security knowledge to all employees and strengthen their awareness of intellectual property protection.

The Company will sign a confidentiality agreement before formal cooperation with third parties. In terms of supplier management, the Company ensures that the Company does not introduce intellectual property risks through procurement by specifying the rights and responsibilities in the contract, regularly conducts intellectual property surveys on suppliers, and performs annual survey reviews of outsourcing projects and suppliers in conjunction with legal, business, procurement, and other relevant departments. In some special cases, special audits of supplier intellectual property rights are initiated. In terms of outsourcing procurement, the Company further strengthens the intellectual property management at the introduction stage of outsourcing suppliers on the basis of the *Outsourcing Procurement Intellectual Property Management System*, quantifies the risk evaluation of proposed outsourcing projects, and strengthens the monitoring and disposal of intellectual property rights during and after outsourcing. The Company also upgrades the *Outsourcing Procurement Intellectual Property Management System*, further implements hierarchical management of outsourcing project information, especially technical packages, and increases occasional audits of strategic outsourcing suppliers.

For internal employees, the Company comprehensively controls the intellectual property risks caused by staff entry or loss from background investigation before joining and training after joining, to non-competition management methods when leaving and intellectual property research and tracking after leaving, and conducts exit reviews for key personnel leaving.

Up to now, the Company has passed all intellectual property audits from clients and has not infringed on their intellectual property rights.



# PROVIDE HIGH-QUALITY SERVICES

- Customer Services
- Quality Management
- Technology Innovation
- Production and Operation
- Sustainable Supply Chain



02



The Company is committed to building a global, end-to-end and comprehensive pharmaceutical service platform. Meanwhile, the Company continuously enhances its core competitiveness, provides its customers with efficient and reliable services, constantly improves customer experience, creates value for customers on an ongoing basis, and enables the public's early access to good medicines.

## CUSTOMER SERVICES

With "Customers First" as one of our core values, we are devoted to creating value for our customers based on a deep understanding of their needs from their perspective. The Company has established a complete process management system for customer development and project management from the preliminary chains such as initial contact with the customers, visit reception, inquiry quotation and project delivery. Taking this as a guide in practical work, we understand customer needs, respond quickly, and provide customized services for different customer needs and project types. In 2022, the Company actively participated in the building of the customer's digital supply chain management, opened up the sharing platform to enable a more transparent and timely interaction of project information, and thus was commended by the customers for the support.

The Company attaches importance to the voice of our customers. By establishing the Customer Experience Management (CEM) system, the Company proactively collects customer feedback information in multiple dimensions with prompt replies, formulates appropriate measures and improvement plans in response to customer comments and suggestions, and continuously follows up on the implementation. Moreover, the Company constantly enhances customer experience and improves service quality through professional and effective communication and quality delivery.

Over the years, the Company has won a number of recognitions from customers and the industry. During the Reporting Period, the Company received many honorary titles such as Leading CDMO Service Provider in 2021 from a large pharmaceutical company, "Top 20 CDMO Pharmaceutical Enterprises in China" and "Top 20 CXO in China", indicating a full affirmation and high acknowledgement from the customers and the industry for its high-quality and reliable services.



*"Strong collaboration on a successful transfer of an important product for Global Public Health."*

*"Your professionalism, timely updates and transparent communication impressed us very much."*

*"Thanks for your update and great work of the team in Shanghai under such a difficult situation, really appreciated!"*

*"Many thanks to Porton for expediting the testing and review to meet our timeline for drug production in the face of limited resources at the end of the year and the impact of the epidemic."*

— Feedback from global customers



## QUALITY MANAGEMENT


5  
REGULATORY  
AUDITS

66  
CUSTOMER  
AUDITS

Quality is the lifeline of pharmaceuticals. As a CDMO that undertakes hundreds of different drug life cycle projects every year, the Company possesses a customer-centric quality culture with full participation and has established a scientific and complete quality management system to meet both the customers' high standards and requirements and the requirements for its own products' flexible production of multiple quantities, various types and multi-functions. The Company is dedicated to implementing quality management in the entire process including product development, production, control, release and other procedures. Moreover, the Company has a professional quality management team. There are more than 570 people in the Company's quality system as of the end of the Reporting Period, accounting for 11% of the total number of employees, to support the smooth development of the Company's quality management.

The Company continues to empower quality management with digital and intelligent transformation. In 2022, the Company developed and launched the Laboratory Information Management System (LIMS) to comprehensively improve QC laboratory's information management in terms of increasing inspection efficiency, reducing human errors as well as enhancing management compliance and transparency. Meanwhile, LIMS opens up the data interaction with Smart Manufacturing Digital System (SMDS) and SAP, which realizes the whole-process information management of materials and products from receipt to release, shortens the release time and improves the efficiency of production inspection and release of the products.

In addition, the Company continues to strengthen the construction of a quality culture and improve the whole-staff awareness of quality management. Through various online and offline training, brainstorming sessions as well as the advancement of methods such as quality pacesetters and teams of quality excellence, knowledge competitions, quality essays and monthly promotional publications of quality, the quality culture is penetrated into all aspects and the whole-staff understanding and awareness of quality knowledge are constantly improved.





## TECHNOLOGY INNOVATION

82

GRANTED INVENTION PATENTS


13

GRANTED PCT PATENTS

95

INVENTION PATENTS UNDER REVIEW

The Company persists in driving high-quality development with technology innovation, strengthens ongoing innovation investment to actively advance the research and development of core technologies and the building of innovative talent teams. As of the end of the Reporting Period, the Company has been granted 82 invention patents (including 71 domestic ones and 11 overseas ones), and 13 PCT patents. Besides, there are 95 invention patents under review. In the past five years, the Company has continued to increase R&D investment and the R&D team has also been in constant expansion. In 2022, the Company invested 519.5 million in R&D, with a year-on-year increase of 91% and a compound annual growth rate of 62% over the past five years. By the end of 2022, there were a total of 1,330 employees in the R&D team, with a year-on-year increase of 46% and a compound annual growth rate of 47% over the past five years.



As always, the Company keeps its continuous exploration of advanced technology and persistently strengthens its R&D technical capabilities through internal construction and external cooperation to provide customers with more valuable services. In terms of API CDMO, the Company continues to explore the technical fields such as crystallization, biocatalysis, continuous manufacturing, HPAPI, SFC and metal catalysis, starts to expand the ability to synthetic macromolecule, and has set up a fast delivery team to focus on R&D services from PCC to toxicology batches. In the field of drug product CDMO, the Company continues to perfect the layout of solubilization technology for insoluble drugs, particle engineering, complex drug product technology and other fields. For gene and cell therapy CDMO, the Company continues to strengthen the capacity of the integrated service platform of plasmid, viral vector and cell therapy. Furthermore, the Company has established a scientific advisory board, the members of which have extensive experience in the pharmaceutical industry and thus can provide the Company with ongoing guidance on technological innovation and layout.

## PRODUCTION AND OPERATION

In terms of API CDMO, the Company has established R&D centers in both China and the United States. The four existing production sites are multipurpose, multifunctional and flexible with a production capacity of nearly 2,100 cubic meters (some capacity transformations are currently in progress). The Company has also built production plants in small, medium and large scales that are suitable for non-GMP and GMP products and equipped them with diversified, multifunctional, flexible and intelligent devices. The installed reactors, with reaction volumes ranging from 20L to 10,000L, have the production capacity to produce customized products with different weight grades from kilogram level to hundred-ton level per year to meet customers' project needs of various phases, indications and products. In 2022, the Company launched the construction of the process development and production base in Slovenia, its first R&D and production operation site in Europe, to further expand its globalization layout and provide global services to customers in a better way. In the field of drug product CDMO, as the first phase of the drug product production base in Liangjiang New District, Chongqing is completed and put into operation, the Company has established the one-stop capability from drug product R&D to production. The drug product production base has three production workshops for solid drug products and two production workshops for injections, with a production capacity covering manufacturing capability for different dosage forms such as oral solids and injectables For gene and cell therapy, as the gene and cell therapy industrial base in Sangtiandao, Suzhou has been completed and put into use in December 2022, the Company has over 20,000 square meters of process development and production workshops, ten production lines of GMP viral vector, 12 production lines of GMP cell therapy, and hundreds of clean workshops to support customer projects from preclinical to commercial production.

Upon the production ramp-up, the Company makes sustained efforts to promote lean operations and optimize the business processes in the main value chain to further improve the multifunctional matching of the Company's production equipment and the scheduling efficiency of production plans. In 2022, the Company developed and launched the Advanced Planning and Scheduling (APS) system to realize the online production scheduling process and capacity information visualization. By means of data linkage with other management systems, the Company has achieved the data integration of the projects in the whole process from inquiry to implementation of the production process, enhancing the production scheduling efficiency, order taking efficiency and transparency of capacity planning management. Additionally, the Company shares lean tools and thinking modes through ways such as lean training, lean monthly promotional publications and the "Golden Idea" platform of improved proposals, and encourages all staff to actively identify and explore improvement and enhancement points to further promote the lean operations.

## SUSTAINABLE SUPPLY CHAIN

A sustainable supply chain and responsible sourcing play an important role in the Company's operations, and a stable and sustainable supply chain is the foundation for the Company to accomplish various deliveries to the customers. Therefore, the Company will always consider building a harmonious supply chain as the target, and work together with the suppliers to build an efficient and sustainable development model. Adhering to the principles such as fairness and justice, complete competition, honesty and self-discipline and quality delivery and service, the Company has developed the supplier screening process and uses it to evaluate potential suppliers in multiple dimensions including technology, quality, supply ability, price, EHS and other dimensions for filtering out qualified suppliers. For suppliers in different categories, the Company has formulated the corresponding management systems, performance management systems and other policies to manage the suppliers in a hierarchical manner. Suppliers are required to comply with the requirements of EHS, human rights, business ethics and other requirements in accordance with the Company's *Supplier Codes of Conduct*. In the meantime, the Company conducts audits, regular performance evaluations and annual reviews of suppliers to evaluate them in multiple dimensions such as quality, on-time delivery rate and service.

The Company identifies potential risks in its supply chain based on the factors such as the external macro environment and develops response plans to ensure the stability of its supply chain. Moreover, the Company continues to increase the number of its strategic suppliers and is devoted to forming an ecosystem to ensure a stable product supply.



# EMPOWER EMPLOYEE DEVELOPMENT

- Employment
- Remuneration and Benefits
- Talent Development
- Employee Communication
- Cultural Co-construction
- Occupational Health and Safety





Talents are the most important resource for the Company. Insisting on the people-oriented talent concept, the Company creates a good working environment and a diversified and inclusive corporate culture, pays attention to the employees' growth and physical and mental health, and continuously improves their sense of security, growth, pleasure, recognition and value.

## EMPLOYMENT


The Company conscientiously implements the *Labor Law of the People's Republic of China*, the *Labor Contract Law of the People's Republic of China* and relevant national and local employment systems and regulations. Meanwhile, it proactively takes a variety of measures to protect human rights, and safeguard the legitimate rights and interests of the employees to create harmonious and stable labor relations. The Company's human rights commitments are clearly reflected in a range of internal policies and supply chain management such as code of conduct, environmental health and safety regulations. These commitments include the respect for basic human rights, guarantee of property and privacy rights, civil and political rights, social and cultural rights, protection of the rights of indigenous peoples and other minorities, and a public commitment to respect the freedom of association and the right of collective bargaining.

100%


LABOR CONTRACT SIGNING RATE

100%

SOCIAL SECURITY COVERAGE



The Company advocates an open, inclusive and diversified corporate culture and thus prohibits any discrimination on the basis of gender, ethnicity, religion, political or other opinions in matters such as hiring, remuneration, working conditions, training opportunities, promotion, dismissal or retirement. When recruiting employees, the Company follows the principle of "openness, fairness and justice" with no forced recruitment. Besides, no forced labor is allowed after the employees join the Company. In the case of overtime needed, the employees are allowed to decide voluntarily and will get the overtime pay according to the regulations if they choose to take the overtime work. Furthermore, the Company explicitly prohibits the use of child labor.



## STABILIZE AND INCREASE JOB POSITIONS TO PROMOTE EMPLOYMENT

In the context of fighting the Covid-19 in the past three years, the Company has achieved to stabilize the existing job positions and increased more to promote employment. As the epidemic frequently spread over to many places and static management was carried out in regions such as Chongqing and Shanghai in 2022, the Company took the initiative to formulate response plans to effectively fulfill its care and responsibility for the employees by paying their salaries normally, providing material security to them and all-round logistic guarantee for those stationed in the field. Guided by business needs, we also constantly increase our job positions to promote social employment through ways such as online and offline multi-form recruitment and school-enterprise cooperation to cultivate talents.



Extraordinary Employer in 2022 by liepin.com [Picture of the Trophy]



Established Strategic Cooperation with the National Engineering Research Center for Industrial Crystallization Technology of Tianjin University [Picture of the Medal]

## REMUNERATION AND BENEFITS

4

INCENTIVE PLANS

320

SENIOR MANAGEMENT PERSONNEL AND CORE BACKBONES COVERED

40.5 million

EXPENDITURE ON EMPLOYEE BENEFITS IN 2022

With consideration of the market pay levels, the Company has established a set of remuneration systems with internal fairness and external market competitiveness based on post value, personal ability and performance, and attracts and retains talents by adopting a combination of short-term, medium-term and long-term incentive models. To improve the long-term incentive mechanism, the Company also makes equity incentives a normal practice to attract, retain and motivate talents, as well as to promote employees to focus on the long-term interests and development goals of the Company. In 2022, the Company launched its Restricted Share Incentive Plan for the fourth consecutive year and granted a total of 5.702 million restricted shares to 211 employees, including middle and senior management staff and core backbones.

In the meantime, the Company on the one hand protects the employees' statutory welfare and enjoyment, and on the other hand has established a diversified, multi-form and multi-level corporate welfare system to meet employees' differentiated needs. It has also built a mechanism to guarantee the welfare of internal talent mobility and enhance the perception of corporate welfare culture.

## TALENT DEVELOPMENT

Adhering to the concept of "Empowering Employees for Common Growth", the Company pays attention on the growth and development of the employees and the improvement of the department and organizational capabilities. With a focus on talent identification, talent training and talent development, the Company has established the effective manpower training system and the dual-channel post system for employees' career development. The systems fit the employee strengths into the corporate strategic development and provide a platform for employees to realize their self-worth, aiming to facilitate Porton's talent development and organizational effectiveness.

**6.45** million  
TRAINING EXPENDITURE

**156,260**  
PERSON-TIME  
EMPLOYEES TRAINED

**90**  
AVERAGE TRAINING  
HOURS PER EMPLOYEE

**| TRAINING SYSTEM**

The Company has formulated the training program based on business needs and post functions for encouraging employees to make continuous progress. In 2022, the Company continued to conduct the standardization construction for its training system by completing the “Seven Stars Plan” project to empower employees at all levels and build its talent cultivation system. Moreover, the Company optimized the internal lectures certification and course accreditation standards, and encouraged employees to settle down and share their knowledge and experience to promote the mutual growth of the team. Furthermore, the training courses have been constantly developed to cover more knowledge and skills in the general and professional fields, and help employees improve their abilities quickly. In addition, we are gradually taking the training-related processes online and thus will be able to plan and implement the training more efficiently with the training data analysis and application.

**| DEVELOPMENT AND MOTIVATION**

The Company conducts performance setting and regular performance reviews for all the employees, and 360-degree feedback evaluations for some managers. By way of the personal performance management mechanism and different kinds of assessment methods, the Company performs an objective and fair assessment of the employees’ performance and contributions to provide effective information for supporting aspects such as employees’ incentive, personal training and development, and career development direction, as well as to promote sustainable binding development of high-performance and high potential talents with the Company. For employees who do not meet the performance requirements, the department shall formulate the plans for performance improvement together with the employees and collaborate with the Human Resource Department to provide the employees with continuous counseling.

The Company has established a qualification system in line with the business and created dual channels for the employees’ career development in terms of management sequence and professional sequence, providing the employees with equal promotion opportunities and multiple channels to choose from for their career development. Moreover, the Company has built a system for job rotation and job transfer to promote talent mobility and diversified development. At the same time, the Company actively pushes forward a two-way communication mechanism between managing officers and employees, values employees’ feedbacks and appeals as well as assists them in sorting through their career development paths.

To facilitate the Company’s overall construction of the talent team, we take regular inventory of the talent status within the organization. This talent review system enables a multi-dimensional check on talent distribution, successors and key positions, and a display of talent panoramic information, while the Individual Development Plan ( “IDP” ) system allows us to realize the online progress tracking of talent development plans. Furthermore, the post system is continuously optimized according to the corporate strategy.

The Company advocates open and honest communication. In addition to providing employees with a variety of communication channels, the Company encourages employees to focus on corporate development, proactively raise their difficulties, problems and suggested solutions, and timely responds to the issues raised by the employees. Moreover, the Company respects employees’ freedom of association and collective bargaining, and thus has established a trade union to give full play to the employees’ roles in democratic management and democratic supervision. The union continuously carries out activities with employee democratic participation and democratic management, and takes the initiative to do real things for the employees to create harmonious and stable labor relations. Furthermore, the Company conducts employee engagement and satisfaction surveys and various questionnaire surveys every year. Based on the data and feedback from the employees, the Company discovers and identifies problems by assessing the grass-roots working environment, and helps management and teams make continuous improvements in the future.

**EMPLOYEE COMMUNICATION**

**CULTURAL CO-CONSTRUCTION**



2022 Porton Cultural Festival themed “Extraordinary Aspirations for a Great Future” was held in Chongqing Grand Theatre on 26 February 2022

The Company regularly carries out diversified sports and theme activities to enrich the employees’ spare-time cultural life. Meanwhile, the Company actively encourages whole-staff participation in the cultural co-construction to build an organizational climate of happiness, vitality, progress, integrity and goodwill, as well as to build a diversified, inclusive corporate culture. To further enhance the influence of the Company’s brand culture, “Xiao Teng” , Porton’s IP, was born in 2022 with the initial image of a deer representing health and longevity and conveying the dynamic and healthy organizational culture of the Company. Moreover, the Company launched a series of activities for the culture month on its 17th anniversary and released the promotional film “Adhering to Science and Love” to demonstrate the cultural features of Porton people seeking truth and goodness.

**OCCUPATIONAL HEALTH AND SAFETY**



Porton Jiangxi obtained ISO45001 Occupational Health and Safety Management System Certification

The Company always considers the employees’ occupational health and production safety as the key for company survival, and strictly complies with the laws and regulations related to occupational health and safety to provide a healthy and safe working environment for the employees. Furthermore, the Company has established a set of EHS management systems based on international best practices and a strict occupational health and safety management system, with the commitment to continuously improve EHS performance and make sustainable investments in resources for perfecting the employees’ working environment.

**0**  
WORK-RELATED DEATHS

**135,627**  
TOTAL EHS TRAINING HOURS

**58.46**  
EHS TRAINING HOURS PER EMPLOYEE

The Company adopts the international process hazard analysis methods of Hazard and Operability Study (HAZOP) and Structured What-if Technique (SWIFT) to perform the systematic analysis of process hazards for all the production processes. At the same time, the Company uses the Risk-based Exposure Assessment (RBEAP) tools to carry out the risk assessments of all chemicals that may be exposed to. In combination of the data from the field tests and analysis, the Company identifies and assesses the risks scientifically, formulates and implements the engineering technological protection measures, management measures and emergency measures to eliminate or reduce various risks that can endanger the employees’ safety and health, as well as to minimize the occupational health risks in the workplace. Moreover, the Company has formulated the safety risk classification management and hidden danger screening management mechanism with a regular review to comprehensively identify risks and hidden dangers as well as to prevent the risks. Furthermore, the Company has prepared emergency plans and strengthened emergency exercises to improve the emergency response capabilities of all the employees.

In the meantime, the Company conducts various special training such as EHS induction training, process safety training, technological hygiene training, safety awareness training and first aid training for the new employees, safety managers and special operators according to the national standards every year. The simulations of emergency exercises are also carried out by the Company annually to improve the employees’ safety awareness and essential skills. Additionally, different departments of the Company organize the EHS activity days to enable the employees’ better grasp of EHS knowledge and skills in diverse forms, which include but are not limited to lectures, discussions, competitions and practices, aiming to penetrate the Company’s safety culture into every aspect.

Besides, we regard good EHS performance as a key factor in choosing contractors, suppliers and other partners, and are committed to pushing forward the EHS compliance construction with relevant parties by including EHS clauses in both procurement and sales contracts.



# PRACTICE GREEN DEVELOPMENT

- EHS Management
- Green Chemistry
- Pollution Governance
- Risk Prevention and Control
- Green, Low Carbon Energy Conservation and Emission Reduction Practices



04




EHS is fundamental to the sustainable development of a CDMO. The Company upholds green development and implements the concept of green chemistry. We continuously consolidate the EHS system and carry out the EHS management and culture throughout all business processes such as R&D and production, so as to avoid, prevent or alleviate the impact on the environment as much as possible through source prevention, process control, and end treatment. In addition, we proactively respond to environmental issues such as climate change to promote the high-quality sustainable development of the Company.

## EHS MANAGEMENT



Porton Jiangxi obtained ISO14001 Environmental Management System Certification




## GREEN CHEMISTRY


The Company strictly abides by relevant environmental laws and regulations, highly values the building of environmental management system, and fully implements the main responsibility of environmental protection. The management of the Company, responsible for the building of the EHS system, work planning and management, performance supervision and improvement, coordinates all departments to earnestly implement the work of EHS. The Company has formulated and released the *Commitment and Policy of the EHS Management* and has developed a set of effective environmental management systems and policies, which are throughout the environmental management involved in the processes of project building and production operation. We have clearly standardized the environmental responsibilities of each department, environmental management objectives, environmental factors identification, assessment and treatment of wastes, environmental monitoring, prevention and control of environmental risks, energy conservation and consumption reduction, carbon emissions, and other various aspects.

In 2022, the Company continued to receive EHS audits and visits from customers and passed the EHS onsite inspections, audits, and visits from customers and regulatory authorities at all levels. During the Reporting Period, the Company won the honors of “Environmental Integrity Enterprise” and “Advanced Entity in Ecological and Environmental Practices” issued by the local authorities.

The Company actively incorporates international advanced green chemistry concepts into the R&D process, adheres to the 12 principles of green chemistry, refuses environmentally harmful reagents, and seeks alternatives through research and development, which includes alternative routes to reduce and replace the use of hazardous reagents. It performs EHS assessments on potentially hazardous steps, optimizes process parameters and control methods, and proactively develops and employs environmentally friendly green pharmaceutical technologies such as biocatalysis, metal catalysis, and continuous reaction to improve product recovery rates, reduce waste generation and emissions, and recover solvents and heavy metals.



12 Principles of Green Chemistry (Anastas, P. T.; Warner, J. C. Green Chemistry: Theory and Practice, Oxford University Press: New York, 1998)



## BIOCATALYSIS

Different from that in conventional chemical catalysts, the catalyst enzyme used in biocatalysis is not resistant to strong acids or alkalis, and usually not resistant to heat, and will be inactivated in many organic solvents. Therefore, biocatalysis requires room temperature, room pressure and a neutral environment and uses water as the solvent, being an energy-saving, carbon emission-reducing and environmental-friendly reaction process natively. By replacing specific reactions in chemical pathways with biocatalysis with the corresponding enzymes, steps can be reduced, yield can be improved and atom economy can be enhanced, so that high energy consumption resulting from high-temperature and high-pressure reactions can be lowered and environmental pressure resulting from the extensive use of organic solvents can be eased. The Company now is capable of fermentation of 1.5L to 300L, meeting customers’ demands for enzymes from milligram-level screening to kilogram-level industrial production. It further extends cooperation to provide customers with all-around biocatalysis solutions covering enzyme development, enzyme screening, enzyme technology development and enzyme manufacturing. In a project for a multinational pharmaceutical company, the Company used biocatalytic technology to reduce two steps from the chemical reaction process, resulting in a doubling of total yield, a 50% reduction in costs and a two-thirds reduction in PMI.

## CONTINUOUS MANUFACTURING

Continuous reaction is a kind of solution synthesis technology in which the solutions of reaction are let flow in specific reaction equipment through a transmission device and raw materials are continuously converted into products that can be collected at the exit. In continuous reactions, raw materials and reagents react quickly with each other in small equipment, so it is safe and has low energy consumption and a flexible scale, and is an important approach for the development of green chemistry for drug synthesis. The Company has applied continuous reaction to R&D, kilogram-level manufacturing, technology transfer, pilot experiments and commercial tonnage production sectors, is experienced in multi-continuous-reaction development and production projects, and is committed to boosting safe, efficient and economic drug production with continuous reaction technology.

## METAL CATALYSIS

The Company’s Chinese and US metal catalysis teams work in synergy with each other to provide metal catalysis DoE services to our customers. We have a trace metal catalytic screening platform based on 24-/96-well plates, which features low sample consumption, high throughput, and high speed. The platform enables the reduction and recovery of highly toxic heavy metal catalysts through the high-throughput screening of the types and dosages of metal catalysts, alkalis, and solvents in metal catalytic reactions. Meanwhile, in order to minimize the risks of damage to EHS, we would try replace heavy metal catalysts with more environmentally friendly and less toxic ones and apply solid-phase loaded catalysts that can be reused and recycled. Besides, we also seek to replace toxic reagents and unfriendly solvents with more environmentally-friendly solvents recommended by the American Chemical Society (ACS). Additionally, metal-catalyzed technology helps to improve reaction yields and reduce costs.

## POLLUTION GOVERNANCE

100%

DISCHARGE STANDARD MEETING RATE OF WASTEWATER

The Company adopts a two-pronged strategy of “source control plus end treatment” . We focus on source control, process improvement, as well as energy conservation and consumption reduction in the production department and guarantee the operation of environmental facilities to meet the standards to actively promote clean production and sustainable development and to minimize the emission of pollutants. We have a special environmentally friendly laboratory, which is used for the scheme formulation of three-waste treatment, monitoring of sewage treatment, self-monitoring of organized exhaust gas, and support of sewage treatment technology.

We carry out strict assaying and management of emissions from our four production bases in Changshou District of Chongqing Municipality, Yichun City of Jiangxi Province, Yingcheng City of Hubei Province, and Fengxian District of Shanghai Municipality, where the pollutant discharges are mainly concentrated, to ensure that the emission is up to standard.

100%

DISCHARGE STANDARD MEETING RATE OF EXHAUST GAS

### | Treatment of wastewater

The wastewater generated by the Company includes production wastewater from production departments, offices, and canteens, rinsing water for equipment and the floor, blowdown water from circulating water, discharge water from boiler rooms, and domestic sewage. We have established corresponding wastewater treatment manuals and equipped wastewater treatment systems and supporting devices with advanced wastewater treatment capacity to meet business development. All wastewater is discharged after treatment in accordance with relevant laws and regulations and local government requirements. As an example, in Changshou District, Chongqing Municipality, the wastewater is treated by the sewage treatment station to meet the accepted standard of the centralized sewage plant in the production base before being discharged to the plant, where advanced treatment is carried out on the wastewater to meet the level-1 standards of national Integrated Wastewater Discharge Standard GB8978-1996 and then the sewage is discharged into the Yangtze River.

100%

COMPLIANCE DISPOSAL RATE OF HAZARDOUS WASTE

### | Treatment of exhaust gas

The Company manages the organized and unorganized exhaust gas emissions in the plants in accordance with relevant exhaust gas management policies. The Company’s exhaust gas mainly comes from production departments, environmental workshops, and sewage treatment workshops and is treated by exhaust gas treatment devices to meet the standards before discharging. Take the production base in Changshou District, Chongqing Municipality as an example. The high-concentration exhaust gas is first condensed by ethylene glycol and washed with alkali, and then incinerated by the Regenerative Thermal Oxidizer (RTO) device to meet the emission standard before discharging. The low-concentration exhaust gas is first condensed by ethylene glycol, then sprayed with alkali and paraffin oil, and adsorbed by activated carbon to meet the emission standard before discharging.

### | Treatment of solid wastes

The Company conducts comprehensive supervision and management of the generation, collection, temporary storage, and treatment of solid wastes to ensure that the whole process is under control. The solid wastes of the Company are mainly caused by the production departments, offices, living areas, and sewage treatment stations. Solid wastes (liquids) are collected and disposed of separately based on the classification of general wastes and hazardous wastes. General industrial solid wastes are recycled or landfilled by qualified solid waste treatment units, domestic wastes are entrusted to the sanitation department for regular cleaning and transportation, and hazardous wastes are entrusted to qualified institutions for disposal and transferred in strict accordance with the requirements of local governments. The Company follows the three principles of “reduction, recycling, and harmlessness” for solid wastes. For recyclable wastes such as cardboard, cartons, and boards, recycling is conducted. For organic solvents, recycling is carried out in the case of satisfying product quality. For sludges in the sewage station, the production of hazardous wastes can be reduced by 50% through sludge drying.

## RISK PREVENTION AND CONTROL

### | Treatment of noise

The Company’s noise is mainly from water ring vacuum pumps, centrifuges, freezers, air compressors, air blowers, and various mechanical pumps in the production departments and sewage stations. Comprehensive management measures such as foundation vibration reduction, sound insulation for buildings, and distance decay are taken to control the noise to ensure compliance of noise emission.

In accordance with the requirements of “clear responsibilities, standardized warning, rapid response, and scientific disposal” of environmental management by crisis, the Company makes substantive efforts in environmental emergency management, aiming at the flammable, explosive, high-temperature, and high-pressure media in the production process with scientific management and strict prevention. Each major production site of the Company has prepared the Risk Assessment Report of Environmental Emergencies and the Emergency Plan for Environmental Incidents, which have been filed in the local environmental protection department. The Company’s production bases have emergency pools to meet the needs of emergency treatment. Meanwhile, the Company continues to improve the EHS-integrated emergency management system. An enhanced team for safety and environmental emergencies has been built. From the preparation of the management system and the plans to the routine exercises of the team, the practical ability of all employees has been improved.

In order to address the environmental impact of climate change, the Company proactively responds to the Paris Agreement’s goal to limit the global average temperature increase to less than two degrees Celsius compared to the pre-industrial period and its long-term goal to strive to limit the temperature increase to within 1.5 degrees Celsius by adopting energy conservation and emission reduction measures to effectively reduce greenhouse gas emissions. The Company evaluates the impact of climate change on the continuity of each business segment and actively formulates measures. We annually account the greenhouse gas emissions, establish carbon reduction targets to make the carbon intensity continuously reduce, and regularly review the continuity and effectiveness of the emission reduction measures.

In the production process, the Company reduces energy consumption through various measures such as adopting variable frequency control for high-powered pumps and forced draught fans, choosing energy-saving suspended aeration fans instead of Roots fans, reusing steam condensate to the sewage tank, and regularly cleaning heat exchangers. In the non-production process, the Company advocates green office and green travel. We actively promote the awareness of energy conservation and emission reduction throughout the Company and organize training for employees in the hope that they can develop the habit of consciously saving energy in their daily production and life and raise their awareness of environmental protection so that each employee can play their part for environmental protection.

## GREEN, LOW CARBON ENERGY CONSERVATION AND EMISSION REDUCTION PRACTICES





# PARTICIPATE IN COMMUNITY CO-DEVELOPMENT

Industrial Cooperation  
Social Welfare



05



A harmonious and healthy social ecology is the basis for the survival and development of an enterprise. The Company proactively participates in the development of the line of business and cooperates with each stakeholder in the line of business for win-win and value creation to promote the harmonious development of society. In addition, we also actively join in social welfare undertakings and feedback to society in various ways to effectively fulfill our corporate social responsibility.

## INDUSTRIAL COOPERATION

The Company actively takes part in international and domestic pharmaceutical guilds, maintains positive interaction with relevant regulatory authorities and guilds, and participates in the discussion and preparation of industry standards and regulations. Additionally, we actively participate in industry exchanges and seminars, and host or join in various forums and salons in the line of business to share our ideas and experiences. We interact harmoniously with our global colleagues in the line of business to expand cooperation, promote mutual benefits, and boost the development of the line of business.

### THE 1<sup>ST</sup> PORTON SUMMIT FOR PHARMACEUTICAL INNOVATION TECHNOLOGY

On 19 and 20 August 2022, the 1<sup>st</sup> Porton Summit for Pharmaceutical Innovation Technology with the theme of “Drive Innovation for Chemical Drugs at the Forefront of Science and Technology” was held in Suzhou, where nearly 30 experts from the pharmaceutical industry shared and discussed innovative hot topics such as API technology and drug product development.



## SOCIAL WELFARE

The Company takes public welfare and charity as effective carriers to pay back to society. We actively participate in public welfare undertakings and pass on the positive energy of sincerity and goodness to society. The Company continues to pay attention to the needs of the community and establishes an institutionalized and normalized “Open Day” system, which builds a platform for communication between the Company and the public in the community and enhances public understanding and trust. Every year, the Company expresses solicitude for the residents, fire department, police, and sanitation workers on the front line of the community and has been awarded the Best Responsible Care Organizational Unit by the Responsible Care Association of Changshou Economic and Technological Development Zone many times. In 2022, the Company launched public welfare program “We Care” and continue to implement social welfare activities.

## SOCIAL ASSISTANCE

### WORKING TOGETHER TO FIGHT THE COVID-19

In 2022, in the context of frequent scattered epidemics across the country, the Company actively joined to fight the epidemic and protect our employees while guaranteeing business continuity. When the epidemic broke out in Suzhou in February, Porton Advanced responded quickly and set up a volunteer team to work round the clock to fully support nucleic-acid testing. In April and May, when Covid-19 broke out in Shanghai, the Company tried its best to open channels and donate materials to Shanghai. In November, when Chongqing was hit by the epidemic, more than 20 employees worked as volunteers.



### DISASTER RELIEF

During the summer heat of Chongqing which caused wildfires in August 2022, the Company actively donated camouflage clothes, towels, straw hats, gloves, fire hoses, and other materials to help fight the fires.







### RURAL REVITALIZATION

The Company actively responded to the strategic goal to consolidate and expand the achievements of poverty alleviation and implement rural revitalization, and proactively participated in the relevant work in combination with its own situation. In May 2022, Porton Jiangxi organized more than 50 volunteers to carry out rural revitalization assistance activities in Ma Butler E-commerce Poverty Alleviation Base in Zhaxia Village, Songbu Town, Fengxin County, Jiangxi Province.

### EDUCATION

The Company pays attention to education and the healthy growth of the next generation. In April 2022, the first “We Care” event was themed “where there are books, there are roads—though we are far away, join me in reading”. We donated books, printers, masks, hand sanitizers, school uniforms, school bags, pens, ink, notebooks, pencils, badminton rackets, basketballs, and table tennis to Dingxing Complete Primary School of Manyue Town Center Primary School in Kaizhou District, Chongqing Municipality. In the same month, the 2022 public welfare activity themed “Love and Sunshine for Children” for Yunji Town Central Primary School - Yang Keming Red Army Primary School, hosted by the Party Committee of the Company and co-organized by the Committee for Caring for Next Generation of Changshou District, Chongqing Municipality and the Comprehensive Party Committee for Enterprises in Changshou Economic and Technological Development Zone, was successfully held. In the activity, we donated books, school bags, and cups to the schools. Besides, the volunteers of the Company also led the children to experience the “Little Chemist” fun experiments.






### HUMAN HEALTH

As a company in the pharmaceutical industry, we are committed to enabling the public’s early access to good medicines and to supporting our customers’ medicines launch with fast and good delivery. Meanwhile, we also contribute to the fight against diseases by increasing publicity to disseminate relevant medicine and disease information to the public. On the 35th World AIDS Day on 1 December 2022, the “We Care” program carried out AIDS awareness activities. We popularized the knowledge of AIDS prevention and treatment and improved the public’s awareness of this through brisk walking and online quizzes.



# KEY PERFORMANCE INDICATORS

INDICATOR TYPE	SPECIFIC INDICATOR	UNIT	2022	2021	
 <b>GOVERNANCE PERFORMANCE</b>					
<b>Operations</b>	Total assets	Billion CNY	10.14	6.56	
	Net asset attributable to shareholders of the listed company	Billion CNY	6.00	3.98	
	Revenue	Billion CNY	7.03	3.11	
	Gross profit	Billion CNY	2.25	0.55	
	Net profit attributable to shareholders of the listed company	Billion CNY	2.01	0.52	
	Total taxes	Million CNY	346.42	91.11	
<b>Business ethics</b>	Training coverage rate of business ethics	%	100	100	
	Lawsuits involving anti-corruption	Number of case	0	0	
 <b>SOCIAL PERFORMANCE</b>					
<b>Products and services</b>	R&D investment	Million CNY	519.51	263.82	
	R&D personnel	Number of people	1,330	913	
	R&D and Technicians	Number of people	1,676	1,201	
	Customer complaint handling rate	%	100	100	
<b>Employees</b>	Total number of employees	Number of people	5,332	3,782	
	By gender	Male	Number of people	3,427	2,442
		Female	Number of people	1,905	1,340
	By age	Below 30	Number of people	2,081	1,414
		30-50	Number of people	2,906	2,078
		Above 50	Number of people	345	290
	By education	Master' s degree and above	Number of people	1,063	703
		Bachelor' s degree	Number of people	2,088	1,334
		Others	Number of people	2,181	1,745
	Proportion of female middle and senior management	%	24	21	
Total net new employees	Number of people	1,550	1,147		
Employee turnover rate	%	13.87	15.47		
Employee training	Person-time	156,260	88,093		
Expenditure on employee training	Million CNY	6.45	5.06		
Employee participation rate in occupational health examination	%	100	100		
Employee engagement	/	4.20	3.86		
Total training hours of EHS	Hour	135,627	/		
Training hours of EHS per employee	Hour	58.46	60.00		
Work-related deaths	Number of people	0	0		
<b>Communities</b>	Donations	Million CNY	0.14	/	

INDICATOR TYPE	SPECIFIC INDICATOR	UNIT	2022	2021
 <b>ENVIRONMENTAL PERFORMANCE</b>				
<b>Environmental management</b>	Environmental expenditure	Million CNY	104.48	65.34
	Purchased electricity	MWh	102,531.40	48,580.16
<b>Energy<sup>1</sup></b>	Purchased steam	Tons	87,427.00	69,848.70
	Natural gas	Cubic meter	1,438,266.00	158,608.00
	Diesel	Liter	30,598.46	19,698.78
	Gasoline	Liter	53,730.82	25,202.32
<b>Greenhouse gas emissions<sup>1</sup></b>	Total direct GHG emissions (Scope 1)	Tons of CO <sub>2</sub> e	20,121.61	26,761.25
	Total indirect GHG emissions (Scope 2)	Tons of CO <sub>2</sub> e	85,495.00	67,599.61
	Total GHG emissions (Scope 1 and 2)	Tons of CO <sub>2</sub> e	105,616.61	94,360.85
<b>Water resource<sup>1</sup></b>	Water consumption	Tons	781,460.60	/
	Wastewater discharged	Tons	692,906	/
	COD discharged	Tons	112.396	/
<b>Wastes discharged<sup>2</sup></b>	NH3-N discharged	Tons	6.94	/
	Exhaust gas emissions	Cubic meter	1,765,928,560	/
	VOC emissions	Tons	45.41	/
	General industrial solid waste	Tons	307.988	/
	Hazardous waste	Tons	10,655.041	/

Note: 1.The data on greenhouse gas emissions do not include the data of operation sites in Suzhou.  
 2.The data of three waste emissions only include the data of operation sites in Chongqing, Jiangxi, Hubei and Fengxian(Gateway Pharmaceutical).



# GRI INDICATOR INDEX

GRI STANDARDS	DISCLOSURE ITEMS	PAGE
<b>GRI 2: General disclosure</b>	2-1 Organizational details	9, 10
	2-2 Entities included in the organization's sustainability reporting	3
	2-3 Reporting period, frequency and contact point	3
	2-6 Activities, value chain and other business relationships	9
	2-7 Employees	27
	2-9 Governance structure and composition	13
	2-10 Nomination and selection of the highest governance body	13
	2-11 Chair of the highest governance body	5
	2-12 Role of the highest governance body in overseeing the management of impacts	13
	2-28 Membership associations	8
	2-29 Approach to stakeholder engagement	6
	<b>GRI 201: Economic Performance</b>	201-1 Direct economic value generated and distributed
<b>GRI 205: Anti-corruption</b>	205-1 Operations assessed for risks related to corruption	16
	205-2 Communication and training about anti corruption policies and procedures	16
	205-3 Confirmed incidents of corruption and actions taken	No such cases
<b>GRI 206: Anti-competition Behavior</b>	206-1 Legal actions for anti-competitive behavior anti-trust, and monopoly practices	No such cases
<b>GRI 302: Energy</b>	302-1 Energy consumption within the organization	44
<b>GRI 303: Water</b>	303-5 Water consumption	44
<b>GRI 305: Emissions</b>	305-1 Direct (Scope 1) GHG emissions	44
	305-2 Energy indirect (Scope 2) GHG emissions	44
<b>GRI 306: Effluents and Waste</b>	306-2 Total amount of waste by category and method of disposal	44
	306-3 Significant spills	No such cases
	306-4 Transport of hazardous waste	35
	<b>GRI 307: Environmental Compliance</b>	307-1 Non-compliance with environmental laws and regulations
<b>GRI 308: Supplier Environmental Assessment</b>	308-1 New suppliers that were screened using environmental criteria	24
	308-2 Negative environmental impacts in the supply chain and actions taken	No such cases
<b>GRI 401: Employment</b>	401-1 New employee hires and employee turnover	43
	401-2 Benefits provided to full-time employees that are not provided to temporary or part-time employees	28

GRI STANDARDS	DISCLOSURE ITEMS	PAGE
<b>GRI 403: Occupational Health and Safety</b>	403-1 Occupational health and safety management	30
	403-2 Hazard identification, risk assessment, and incident investigation	30
	403-5 Worker training on occupational health and safety	30
	403-8 Workers covered by an occupational health and safety management system	30
<b>GRI 404: Training and Education</b>	404-1 Average hours of training per year per employee	29
	404-2 Programs for upgrading employee skills and transition assistance programs	29
	404-3 Percentage of employees receiving regular performance and career development reviews	29
<b>GRI 405: Diversity and Equal Opportunity</b>	405-1 Diversity of governance bodies and employees	13, 27
<b>GRI 406: Non-discrimination</b>	406-1 Incidents of discrimination and corrective actions taken	No such cases
<b>GRI 407: Freedom of Association and Collective Bargaining</b>	407-1 Operations and suppliers in which the right to freedom of association and collective bargaining may be at risk	No such cases
<b>GRI 408: Child Labor</b>	408-1 Operations and suppliers at significant risk for incidents of child labor	No such cases
<b>GRI 409: Forced or Compulsory Labor</b>	409-1 Operations and suppliers at significant risk for incidents of forced or compulsory labor	No such cases
<b>GRI 411: Rights of Indigenous People</b>	411-1 Incidents of violations involving rights of indigenous peoples	No such cases
<b>GRI 412: Human Rights Assessment</b>	412-2 Employee training on human rights policies or procedures	27
	<b>GRI 413: Local Communities</b>	413-1 Operations with local community engagement impact assessments, and development programs
413-2 Operations with significant actual and potential negative Impacts on local communities		No such cases
<b>GRI 414: Supplier Social Assessment</b>	414-1 New suppliers that were screened using social criteria	24
	414-2 Negative social impacts in the supply chain and actions taken	No such cases
<b>GRI 416: Customer Health and Safety</b>	416-2 Incidents of non-compliance concerning the health and safety impacts of products and services	No such cases
<b>GRI 417: Marketing and Labelling</b>	417-2 Incidents of non-compliance concerning product and service information and labelling	No such cases
	417-3 Incidents of non-compliance concerning marketing communication	No such cases
<b>GRI 418: Customers Privacy</b>	418-1 Substantiated complaints concerning breaches of customer privacy and losses of customer data	No such cases
<b>GRI 419: Socioeconomic Compliance</b>	419-1 Non-compliance with laws and regulations in the social and economic area	No such cases



# FEEDBACK FORM

Dear Readers,

We appreciate your time for reading this Report. We sincerely look forward to your feedback and valuable opinions to help us improve our social responsibility performance and enhance our ability to fulfill our social responsibilities.

**1** What is your overall rating of Porton’s fulfillment of social responsibility?

very good  good  average  poor  very poor

**2** What is your overall rating of this Report?

very good  good  average  poor  very poor

**3** What do you think of Porton’s performance in stakeholder communication?

very good  good  average  poor  very poor

**4** What do you think of Porton’s performance in corporate governance?

very good  good  average  poor  very poor

**5** What do you think of Porton’s performance in industrial responsibility?

very good  good  average  poor  very poor

**6** What do you think of Porton’s performance in employee responsibility?

very good  good  average  poor  very poor

**7** What do you think of Porton’s performance in environmental responsibility?

very good  good  average  poor  very poor

**8** What do you think of Porton’s performance in social responsibility?

very good  good  average  poor  very poor

**9** Do you think the content and layout of this Report are reader friendly?

yes  no

**10** What are your comments and suggestions on Porton’s fulfillment of social responsibility and this Report?



**Scan the QR code  
We appreciate your  
valuable feedback!**